The Latest Breaking News from Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) shares are trading lower by 3.42% to $263.88 during Monday’s pre-market session after the company announced VX-880 Phase 1/2 has been placed on clinical hold by the FDA due to “a determination that there is insufficient information to support do

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 15 years by 8.29% on an annualized basis producing an average annual return of 15.84%. Currently, Vertex Pharmaceuticals has a market capitalization of $72.91 billion.

The Dow Jones fell as President Joe Biden tapped the nation's emergency oil reserves. The Fed's favorite inflation gauge spiked.

Elsewhere, Paychex rose over 1% and moved above a proper buy point.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released positive results from two Phase 2 post-operative trials for its non-opioid program, VX-548.  One trial looked at patients who had just received a bunionectomy (Correcting the deformity of toes & foot), the other in patients who received abdominoplasty (tummy tuck). Vertex said that within 48 hours of surgery,…

The stock market traded lower as President Biden prepared to release oil reserves, sending oil prices lower.

The Dow Jones fell after President Biden unveiled tax hikes. Tesla stock soared on split news. Microsoft was up while AMC stock exploded.

Vertex Pharmaceuticals has been outperforming and ranks second in the biotech industry group.

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 9.35% on an annualized basis.